Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Leng S, Bhutani D, Raza S, Assal A, Pan S, Hu J, Wei A, Mapara M, Lentzsch S.

Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5. No abstract available.

2.

How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Leng S, Bhutani D, Lentzsch S.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):125-136. doi: 10.1182/hematology.2019000016.

PMID:
31808850
3.

One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Wall JS, Solomon A, Eisenberger A, Lentzsch S.

Amyloid. 2019;26(sup1):115-116. doi: 10.1080/13506129.2019.1584892. No abstract available.

PMID:
31343323
4.

Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.

Bhutani D, Leng S, Lentzsch S.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):555-559. doi: 10.1016/j.clml.2019.03.029. Epub 2019 Apr 1. Review.

PMID:
31262668
5.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
6.

Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.

Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, Wright JD, Hershman DL, Lentzsch S, Neugut AI.

J Natl Compr Canc Netw. 2019 Jan;17(1):22-28. doi: 10.6004/jnccn.2018.7079.

7.

Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation.

Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P.

Bone Marrow Transplant. 2019 Jan;54(1):164-167. doi: 10.1038/s41409-018-0270-x. Epub 2018 Jul 23. No abstract available.

8.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

9.

A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation.

Modi D, Al-Kadhimi Z, Chen W, Jang H, Deol A, Ayash L, Bhutani D, Alavi A, Ratanatharathorn V, Uberti JP.

Am J Hematol. 2018 Aug;93(4):E96-E98. doi: 10.1002/ajh.25035. Epub 2018 Feb 5. No abstract available.

10.

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP.

Bone Marrow Transplant. 2017 Nov;52(11):1530-1536. doi: 10.1038/bmt.2017.182. Epub 2017 Sep 4.

11.

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.

Bhutani D, Zonder JA.

Blood Lymphat Cancer. 2017 Jul 19;7:53-60. doi: 10.2147/BLCTT.S82444. eCollection 2017. Review.

12.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.

Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19.

13.

Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP.

Support Care Cancer. 2017 Aug;25(8):2593-2601. doi: 10.1007/s00520-017-3670-3. Epub 2017 Apr 2.

14.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

15.

Collapsing glomerulopathy associated with hemophagocytic syndrome in a patient with NK/T cell lymphoma.

Gebregeorgis W, Patel I, Thakur M, Bhutani D, Woldie I.

Clin Nephrol Case Stud. 2016 Jun 27;4:11-17. doi: 10.5414/CNCS108586. eCollection 2016.

16.

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Uberti JP.

Am J Hematol. 2016 Sep;91(9):E341-7. doi: 10.1002/ajh.24435. Epub 2016 Jul 14.

17.

Activated T cells armed with bispecific antibodies kill tumor targets.

Bhutani D, Lum LG.

Curr Opin Hematol. 2015 Nov;22(6):476-83. doi: 10.1097/MOH.0000000000000176. Review.

PMID:
26457960
18.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
19.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. doi: 10.1016/j.bbmt.2014.10.004. Epub 2014 Oct 16.

20.

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.

Ratanatharathorn V, Deol A, Ayash L, Cronin S, Bhutani D, Lum LG, Abidi M, Ventimiglia M, Mellert K, Uberti JP.

Bone Marrow Transplant. 2015 Jan;50(1):106-12. doi: 10.1038/bmt.2014.203. Epub 2014 Oct 6.

Supplemental Content

Loading ...
Support Center